PEPG vs. TRDA, CRBP, BMEA, TBPH, MRSN, MREO, SLRN, ANNX, LXRX, and AMRN
Should you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Entrada Therapeutics (TRDA), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), Theravance Biopharma (TBPH), Mersana Therapeutics (MRSN), Mereo BioPharma Group (MREO), Acelyrin (SLRN), Annexon (ANNX), Lexicon Pharmaceuticals (LXRX), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
PepGen (NASDAQ:PEPG) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
Entrada Therapeutics has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Entrada Therapeutics had 10 more articles in the media than PepGen. MarketBeat recorded 13 mentions for Entrada Therapeutics and 3 mentions for PepGen. Entrada Therapeutics' average media sentiment score of 1.16 beat PepGen's score of 0.30 indicating that Entrada Therapeutics is being referred to more favorably in the news media.
58.0% of PepGen shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 4.0% of PepGen shares are owned by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
PepGen currently has a consensus target price of $24.67, indicating a potential upside of 76.06%. Entrada Therapeutics has a consensus target price of $21.00, indicating a potential upside of 46.44%. Given PepGen's higher probable upside, research analysts plainly believe PepGen is more favorable than Entrada Therapeutics.
PepGen received 1 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. Likewise, 85.71% of users gave PepGen an outperform vote while only 73.33% of users gave Entrada Therapeutics an outperform vote.
PepGen has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.
Entrada Therapeutics has a net margin of 14.42% compared to PepGen's net margin of 0.00%. Entrada Therapeutics' return on equity of 9.73% beat PepGen's return on equity.
Summary
Entrada Therapeutics beats PepGen on 11 of the 15 factors compared between the two stocks.
Get PepGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
